Login to Your Account



Synairgen Raises £6.35M for Asthma, COPD Work

By Nuala Moran


Wednesday, June 3, 2009
LONDON - Synairgen plc has succeeded in raising £6.35 million (US$10.3 million) in a placing of 37 million shares at a minimal discount of 4.23 percent to fund proof-of-concept trials for inhaled interferon beta in treating exacerbations of asthma and chronic obstructive pulmonary disorder (COPD) caused by the common cold virus. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription